Study guide
12.2 Sterile Compounding & USP <797> Standards
Utah MPJE Pharmacy Jurisprudence Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Utah Pharmacy Regulatory Framework, Facility Licensing & the PIC
1.1 DOPL, the Utah State Board of Pharmacy & the Sources of Utah Pharmacy Law 1.2 Federal vs. Utah Law: Following the Stricter Standard 1.3 Utah Pharmacy License Classes (A–E) & Facility Licensing 1.4 The Pharmacist-in-Charge (PIC): Duties, Self-Audits & Notifications 1.5 Facility Inspections, Ownership & Location Changes, Closing & Facility Discipline
2 Chapter 2: Pharmacist, Intern & Technician Licensure and Personnel
2.1 Pharmacist Licensure, the NAPLEX & Utah MPJE, and Licensure by Endorsement 2.2 License Renewal, Continuing Education & Reinstatement 2.3 Pharmacy Interns & Preceptors 2.4 Pharmacy Technicians, Technician Trainees & Supportive Personnel
3 Chapter 3: Unlawful & Unprofessional Conduct, Discipline, and Impairment
3.1 Unlawful Conduct, Criminal Penalties, Fines & the Disciplinary Process 3.2 Unprofessional Conduct, the APhA Code of Ethics & Utah's Conscience Law 3.3 Impairment, the Utah Professionals Health Program & Reinstatement
4 Chapter 4: Prescription Issuance, Prescriber Authority & Electronic Prescribing
4.1 Prescriber Scope of Authority in Utah 4.2 Required Prescription Elements, Oral & Faxed Orders, and Alterations 4.3 Mandatory Electronic Prescribing of Controlled Substances (EPCS) in Utah 4.4 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags
5 Chapter 5: Patient Counseling, Prospective DUR, Confidentiality & Records
5.1 Patient Counseling: The Offer, Who May Counsel & Delivered Prescriptions 5.2 Prospective Drug Utilization Review & Patient Medication Profiles 5.3 Confidentiality, HIPAA & Protected Health Information 5.4 Pharmacy Records, Retention Periods & Facility Operating Standards
6 Chapter 6: Expanded Practice: Collaboration, Pharmacist Prescribing & Drug Administration
6.1 Collaborative Pharmacy Practice, Drug Therapy Management & Administration of Drugs 6.2 Self-Administered Hormonal Contraception: Standing Order & Pharmacist Prescribing 6.3 Pharmacist Prescribing Under Utah Code § 58-17b-627: Tobacco Cessation, HIV PrEP/PEP, Fluoride & Epinephrine 6.4 Vaccine Administration: DOPL's Protocol, Delegation, Emergencies & USIIS Reporting
7 Chapter 7: Opioid Overdose Prevention, Emergency Refills & Returned or Donated Drugs
7.1 Naloxone & Opioid-Safety Laws in Utah 7.2 Emergency Refills, Combined Refills & Insulin Continuity 7.3 Returned Drugs, Consumer Disposal & the Charitable Prescription Drug Recycling Program
8 Chapter 8: Controlled Substance Schedules, Registration & Security in Utah
8.1 Controlled Substance Schedules: Federal CSA & Utah-Specific Scheduling 8.2 DEA Registration & Facility Licensing 8.3 Controlled Substance Storage & Physical Security
9 Chapter 9: Dispensing Controlled Substances & the Utah Controlled Substance Database
9.1 Schedule II Prescriptions: 30-Day Window, One-Month Supply, Multiple Prescriptions & the 7-Day Acute Limit 9.2 Schedule II Partial Fills, Emergency Oral Orders & Methadone Emergency Orders 9.3 Schedule III–V Prescriptions: Refill Limits, the 80% Rule & Controlled Substance Transfers 9.4 The Utah Controlled Substance Database (CSD)
10 Chapter 10: Dispensing Standards: Labeling, Substitution, Refills, Packaging, Product Integrity & OTC Products
10.1 Prescription Labels: Utah Minimum Elements, Controlled Substance & Opioid Warnings, and Special Labels 10.2 Drug Product Selection: Generic Equivalents, Therapeutically Similar Drugs & Interchangeable Biologics 10.3 Legend-Drug Prescription Validity, Refills & Transfers 10.4 Poison Prevention Packaging Act (PPPA) & Special Packaging 10.5 Drug Product Conditions That Prohibit Dispensing: Adulterated, Misbranded, Outdated, Recalled & Suspect Products 10.6 Nonprescription Products: OTC Labeling & Packaging, Pseudoephedrine, Iodine, Schedule V & Other Restricted OTC Sales
11 Chapter 11: Acquisition, Inventory, Loss, Distribution & Delivery
11.1 Ordering Schedule II Substances: DEA Form 222 & CSOS 11.2 Controlled Substance Inventories & Utah's Schedule II Perpetual Inventory 11.3 Theft, Significant Loss & Disposal of Controlled Substances 11.4 Drug Acquisition & Distribution, Office-Use Sales, and Delivering Prescriptions to Patients
12 Chapter 12: Compounding Standards, USP Chapters & Hazardous Drugs
12.1 Non-Sterile Compounding & USP <795> Standards 12.2 Sterile Compounding & USP <797> Standards 12.3 Hazardous Drug Handling & USP <800> Standards
13 Chapter 13: Institutional, Central Processing, Remote Dispensing, Specialty Outlets & Automation
13.1 Institutional Practice: Hospitals, Pharmaceutical Administration Facilities & Emergency Drug Kits 13.2 Centralized Prescription Processing, Telepharmacy & Remote Dispensing Pharmacies 13.3 Nuclear Pharmacies, Class E Outlets & Dispensing Medical Practitioners 13.4 Automated Pharmacy Systems, Quality Assurance & Pharmacy Audits
12.2 Sterile Compounding & USP <797> Standards
Key Takeaways Explain This Topic AI
Primary Engineering Controls (PECs) such as laminar airflow workbenches must maintain ISO Class 5 air, buffer cleanrooms must maintain ISO Class 7, and anterooms opening into positive-pressure areas must maintain at least ISO Class 8.
Non-hazardous sterile cleanrooms require positive pressure airflow (minimum 0.02 inches water column) from the buffer room outward to the anteroom to prevent airborne particulate contamination.
Initial personnel qualification mandates passing three consecutive gloved fingertip tests with zero colony-forming units (CFUs) on both hands, followed by periodic media-fill and fingertip testing every 6 months for Category 1 and Category 2 CSPs.
Under revised USP <797>, Compounded Sterile Preparations (CSPs) are classified into Category 1 (prepared in a Segregated Compounding Area; BUD ≤12 hours room temp or ≤24 hours refrigerated), Category 2 (prepared in an ISO 7 cleanroom suite; BUD based on sterility testing and components), and Category 3 (enhanced testing; BUDs up to 60-180 days).
Immediate-use CSPs are restricted to emergency or emergent clinical situations; administration must begin within a strict 4-hour window from the start of preparation or be discarded.
Last updated: September 2026
12.2 Sterile Compounding & USP <797> Standards
Sterile compounding encompasses the preparation of medications intended for parenteral administration, ophthalmic instillation, pulmonary inhalation, or tissue irrigation that must be completely free from viable microorganisms, pyrogens, and particulate matter. Microbial contamination in sterile preparations carries grave clinical consequences, including systemic bacteremia, fungal meningitis, and sepsis. To protect the public, the United States Pharmacopeia established USP General Chapter <797> (Pharmaceutical Compounding – Sterile Preparations), which Utah requires every compounding licensee to follow under Utah Admin. Code R156-17b-614e . Utah modifies one element: a smoke study is required only for new construction of a facility or when equipment is physically moved within the cleanroom. Failing to comply with USP <797> is unprofessional conduct (R156-17b-502(2)). Nuclear pharmacies preparing sterile compounds follow USP <797> (R156-17b-614d(8)), and remote dispensing pharmacies may not compound at all (R156-17b-614g(3)). Pharmacists preparing for the Utah MPJE must demonstrate command of cleanroom engineering controls, ISO air quality classifications, rigorous personnel garbing protocols, competency verification testing, beyond-use dating across CSP categories, and the operational parameters governing immediate-use emergency exemptions.
Cleanroom Architecture & ISO Cleanliness Classifications
Sterile compounding relies on a nested architectural system of primary and secondary engineering controls to progressively eliminate airborne environmental particulates. The International Organization for Standardization (ISO) classifies air cleanliness by the maximum allowable concentration of airborne particulates per cubic meter of air:
Primary Engineering Controls (PECs) — ISO Class 5
The Primary Engineering Control is the device or zone that provides an ISO Class 5 environment (containing no more than 3,520 particles of size 0.5 µm or larger per cubic meter of air). The critical work area inside the PEC is the Direct Compounding Area (DCA), where critical sites (such as open vial septa, ampule necks, and needle hubs) are exposed to unidirectional, HEPA-filtered "first air":
Laminar Airflow Workbenches (LAFW) : Deliver horizontal or vertical unidirectional HEPA air; used exclusively for non-hazardous sterile compounding.
Biological Safety Cabinets (BSC) : Vertical laminar flow hoods that exhaust air outward or through dedicated filtration; Class II BSCs provide ISO Class 5 air.
Compounding Aseptic Isolators (CAI) : Glove-box barrier isolators that maintain ISO Class 5 positive pressure for non-hazardous sterile preparations.
Secondary Engineering Controls (SECs) — Cleanroom Suite
The Secondary Engineering Control is the enclosed area that houses the PEC and serves as the controlled environment supporting aseptic operations:
Buffer Room (Cleanroom) — ISO Class 7 : The room where the PEC is physically situated. Must achieve ISO Class 7 air cleanliness (maximum 352,000 particles of size 0.5 µm or larger per cubic meter). Walls, floors, and ceilings must be non-porous, smooth, monolithic, and crack-free. The buffer room may not contain plumbed water sources such as sinks, eyewashes, showers, or floor drains, and the anteroom may not contain floor drains.
Anteroom — ISO Class 8 or Class 7 : The transitional area connecting the unclassified pharmacy area to the buffer room. Used for staging supplies, gowning, hand hygiene, and order entry:
For non-hazardous sterile compounding (positive pressure cleanroom suite), the anteroom must achieve at least ISO Class 8 air cleanliness (maximum 3,520,000 particles/m³).
If the anteroom opens into a negative-pressure buffer room (used for hazardous drug compounding), the anteroom must meet the stricter standard of ISO Class 7 .
Pressure Differentials & Airflow Dynamics
To prevent airborne particulates from migrating from less clean areas into cleaner rooms, non-hazardous sterile compounding cleanroom suites must maintain a continuous positive pressure differential :
The non-hazardous buffer room must maintain a positive pressure of at least 0.020-inch water column relative to the anteroom.
The anteroom must maintain at least 0.020-inch water column positive pressure relative to the unclassified area.
A pressure monitoring device must monitor the differentials continuously, and results must be reviewed and documented at least daily on days when compounding occurs.
Area / Control Type ISO Air Cleanliness Class Particle Limit (≥0.5 µm/m³) Required Pressure Differential Permissible Fixtures / Restrictions
Primary Engineering Control (PEC) ISO Class 5 ≤ 3,520 Unidirectional positive airflow Direct Compounding Area (DCA); no unsterilized supplies
Buffer Area (Cleanroom) ISO Class 7 ≤ 352,000 Positive (≥ 0.020" w.c.) relative to anteroom No sinks, eyewashes, showers, or floor drains
Anteroom (Positive Suite) ISO Class 8 ≤ 3,520,000 Positive (≥ 0.020" w.c.) relative to unclassified area No floor drains; hand-hygiene sink may be inside or outside
Anteroom (Negative Suite) ISO Class 7 ≤ 352,000 Positive relative to unclassified spaces Required when opening to negative HD buffer room
Important
Plumbed water sources are banned from the buffer room. In a cleanroom suite, the hand-hygiene sink may be inside or outside the anteroom. If it is inside, it may be on either the clean or the dirty side, and the order of hand washing and garbing depends on where it is. In a segregated compounding area, a sink may not be within 1 meter of the PEC.
Personnel Hygiene, Garbing Protocol & Competency Evaluations
Human personnel are the greatest source of particulate shedding and microbial contamination in cleanroom environments. USP <797> requires garbing in an order, written in the facility's SOPs, that reduces contamination risk. A typical dirtiest-to-cleanest sequence:
Order of Garbing and Hand Hygiene
Personal Preparation : Remove all outer garments (jackets, sweaters), watches, jewelry, rings, and cosmetics/nail polish. Artificial nails are strictly banned.
Shoe Covers : Don dedicated shoes or shoe covers before crossing the line of demarcation.
Head and Facial Covers : Don head cover and facial hair covers (beard/mustache covers), ensuring all hair is securely tucked inside.
Face Mask : Don a face mask. Eye protection is added when SOPs or hazardous-drug handling require it.
Hand Hygiene : Clean under the fingernails under warm running water with a disposable nail cleaner, then wash hands and forearms to the elbows with soap and water for at least 30 seconds . Dry completely with low-lint disposable towels or wipers. Brushes and hand dryers are not used, and soap containers are not refilled or topped off.
Non-Shedding Gown : Don a non-shedding, clean compounding gown with snug cuffs and a closed neck.
Hand Antisepsis : Apply an alcohol-based hand rub before donning sterile gloves and let hands dry completely.
Sterile Gloves : Don sterile, powder-free gloves in a classified room or SCA (never inside the PEC), ensuring the gloves completely cover the cuffs of the gown sleeves. Periodically disinfect gloves with sterile 70% IPA throughout compounding.
Competency Verification: Fingertip Sampling & Media-Fill Testing
Every individual who compounds or directly supervises sterile preparations must undergo rigorous competency evaluations:
Gloved Fingertip and Thumb Sampling (GFT) :
Initial Qualification : Before compounding independently, personnel must pass an initial hand hygiene and garbing competency, including gloved fingertip and thumb sampling of both hands, no fewer than three separate times . The action level is more than 0 CFU (total for both hands). Samples are taken before sterile 70% IPA is applied to the gloves.
Ongoing Competency : Tested periodically following a media-fill test (at least every 6 months for Category 1 and Category 2 CSPs; every 3 months for Category 3 CSPs). The action level for ongoing testing is greater than 3 CFUs total across both hands.
Media-Fill Testing :
Simulates the most challenging, complex aseptic manipulation steps using sterile soybean-casein digest medium (tryptic soy broth).
Incubated for a total of 14 days (typically 7 days at 20°C-25°C followed by 7 days at 30°C-35°C).
Failure Standard : Any turbidity, cloudiness, or visible microbial growth in any container indicates a test failure.
Frequency : Initial qualification, and at least every 6 months for Category 1 and Category 2 CSPs, and at least every 3 months for Category 3 CSPs.
CSP Categories & Beyond-Use Dating Under Revised USP <797>
The revised USP <797> replaced the historic low-, medium-, and high-risk compounding categories with an objective, facility-based three-tier framework: Category 1, Category 2, and Category 3 Compounded Sterile Preparations (CSPs) :
Category 1 Compounded Sterile Preparations
Compounding Environment : Prepared in an ISO Class 5 Primary Engineering Control situated within an unclassified Segregated Compounding Area (SCA) or a PEC that lacks an ISO Class 7 buffer cleanroom suite.
Air Cleanliness : PEC is ISO Class 5, but the surrounding room is not ISO classified.
Beyond-Use Date Limits :
Controlled Room Temperature (20°C to 25°C): Maximum 12 hours .
Refrigerated (2°C to 8°C): Maximum 24 hours .
Frozen (-25°C to -10°C): Not permitted .
Category 2 Compounded Sterile Preparations
Compounding Environment : Prepared in an ISO Class 5 PEC inside a cleanroom suite : an ISO Class 7 buffer room with an ISO Class 8 (or better) anteroom.
BUD limits (USP <797> Table 13) depend on the compounding method, sterility testing, starting components, and storage:
- Category 2 method Sterility test passed? Room temp (20°C–25°C) Refrigerator (2°C–8°C) Freezer (−25°C to −10°C)
- Aseptically processed, one or more nonsterile starting components No 1 day 4 days 45 days
- Aseptically processed, only sterile starting components No 4 days 10 days 45 days
- Aseptically processed Yes 30 days 45 days 60 days
- Terminally sterilized No 14 days 28 days 45 days
- Terminally sterilized Yes 45 days 60 days 90 days
Sterility testing follows USP <71> or a validated alternative. Category 2 injectables compounded from one or more nonsterile components and assigned a BUD that requires sterility testing must also be tested for bacterial endotoxins. Terminal sterilization (such as steam, dry heat, or irradiation in the final container) earns longer BUDs than aseptic processing.
Category 3 Compounded Sterile Preparations
Compounding Environment : Also prepared in a cleanroom suite, with added requirements that apply to everyone entering the buffer room: sterile low-lint outer garb with no exposed skin, more frequent environmental monitoring and sporicidal cleaning, and garbing, fingertip, and media-fill requalification every 3 months . Every batch must be sterility tested and pass all applicable tests, including endotoxin testing where required and a stability-indicating assay. Batches may not exceed 250 final yield units .
BUD limits (USP <797> Table 14) : Aseptically processed: 60 days room temperature, 90 days refrigerated, 120 days frozen. Terminally sterilized: 90, 120, and 180 days . A shorter BUD applies when stability data support less.
CSP Category Where Prepared Maximum BUD
Category 1 ISO Class 5 PEC in a segregated compounding area (or cleanroom suite) 12 hours room temp; 24 hours refrigerated
Category 2 ISO Class 5 PEC in a cleanroom suite 1 to 90 days depending on method, testing, and storage (Table 13)
Category 3 Cleanroom suite plus Category 3 controls 60 to 180 days (Table 14)
Immediate-Use Outside classified areas when delay would harm the patient Administration must begin within 4 hours of the start of preparation
Immediate-Use CSP Exemption & Administration Timelines
USP <797> provides an explicit exemption for emergency or urgent clinical situations where immediate administration is critical to prevent patient harm or death (e.g., cardiopulmonary resuscitation in an emergency department, code blue, rapid sequence intubation, or emergent operating room stabilization):
Exemption Scope : Immediate-use CSPs are exempt from ISO Class 5 PEC, ISO Class 7 buffer room, and garbing mandates, provided basic aseptic technique is observed.
Conditions : Written SOPs, trained personnel, aseptic technique, evidence-based physical and chemical compatibility, no more than three different sterile products , and discard of any unused starting component from a single-dose container. Only sterile products may be used. Unless the preparer administers the CSP or witnesses its administration, it must be labeled with the names and amounts of all active ingredients, the preparer's name or initials, and the exact 4-hour period within which administration must begin.
Strict 4-Hour Administration Window : Under the revised USP <797> standards, administration must begin within four (4) hours of the start of the preparation (updated from the older 1-hour requirement). If administration has not begun within four hours, the preparation must be immediately discarded.
Warning
The 4-hour clock for immediate-use CSPs begins at the start of preparation , not when compounding is completed, and not when the nurse hangs the bag. Immediate-use provisions are only for situations where preparing the CSP under Category 1, 2, or 3 conditions would delay therapy and add risk to the patient.
Common MPJE Traps & Scenario Analysis
The SCA Beyond-Use Trap : An IV piggyback compounded inside an ISO Class 5 hood located in an unclassified satellite pharmacy workroom (a Segregated Compounding Area). A candidate assigns a 9-day refrigerated BUD based on sterile ingredients. Exam Trap : Because the PEC is situated in an SCA and not a certified ISO Class 7 cleanroom suite, the preparation is a Category 1 CSP , capping the maximum refrigerated BUD at 24 hours .
Immediate-Use Timeline Revisions : An exam question asks for the beyond-use limit of an epinephrine drip mixed during a code blue at the bedside. Older prep materials cite 1 hour. Under the revised USP <797>, the correct legal limit is 4 hours .
Initial Fingertip Sampling Passing Standard : A new technician achieves 1 CFU on their left hand and 0 CFUs on their right hand during an initial gloved fingertip evaluation. Exam Trap : The initial action level is more than 0 CFU for both hands combined, across at least three separate evaluations. A count of 1 CFU exceeds the action level and requires investigation, retraining, and retesting.
Cleanroom Sink Placement : A cleanroom design proposal includes installing a stainless steel handwashing sink inside the ISO Class 7 buffer area. Exam Trap : Under USP <797>, the buffer room may not contain sinks or other plumbed water sources. The hand-hygiene sink goes inside the anteroom (clean or dirty side) or outside it in a clean space.